{"product_id":"servier-pestle-analysis","title":"Servier PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Shortcut to Market Insight Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how political, economic, social, technological, legal, and environmental forces are reshaping Servier’s strategy and risks. This concise PESTLE snapshot highlights regulatory pressures, market dynamics, and innovation drivers you can act on. Perfect for investors and strategists needing ready-to-use intelligence. Purchase the full analysis to unlock detailed recommendations and data-ready charts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDrug pricing and HTA pressures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePrice controls and health-technology assessments in the EU, UK and many markets shape Servier’s reimbursement and margins; the EU HTA Regulation entered into application in January 2025 and NICE uses a £20,000–30,000\/QALY threshold, intensifying evidence demands. Strategic early payer engagement and robust outcomes data are critical, as negative appraisals or delays can stall launches for months.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic funding and R\u0026amp;D incentives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEU Horizon Europe (≈€95.5bn 2021–27) and France’s research tax credit (CIR ≈€6–7bn annually) shape Servier’s R\u0026amp;D footprint, and the group reported ~€1.1bn R\u0026amp;D spend in 2023, leveraging grants and innovation funds to expand pipelines.\u003c\/p\u003e\n\u003cp\u003eShifts in national life‑science strategies reallocate incentives toward oncology or cardio‑metabolic programs, altering target prioritization and clinical sequencing.\u003c\/p\u003e\n\u003cp\u003eStable public support preserves pipeline optionality and de‑risks long, capital‑intensive programs; policy reversals increase effective cost of capital and funding gaps for late‑stage assets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitics and supply chain resilience\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGeopolitical tensions and export controls increasingly strain access to APIs, biologics inputs and specialized equipment, with roughly 60% of global APIs sourced from China and India. Localization policies in 2024 have pushed governments to require regional manufacturing commitments, prompting capacity expansion. Diversification and dual-sourcing are widely adopted to mitigate disruption risk. Political instability can delay site activation and has reduced trial starts in affected countries by ~10%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic procurement and hospital formularies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTendering practices in hospitals drive price competition and volume; EU public procurement equals about 14% of GDP, intensifying margin pressure for manufacturers. Centralized purchasing compresses margins but secures scale—Servier reported €4.9bn revenue in 2023, where hospital contracts matter for volume. Demonstrating real-world outcomes supports preferential formulary placement, while political moves toward procurement transparency can shift award dynamics.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTendering: price-led, volume-bearing\u003c\/li\u003e\n\u003cli\u003eCentralized buying: lower margins, higher scale\u003c\/li\u003e\n\u003cli\u003eReal-world evidence: boosts formulary access\u003c\/li\u003e\n\u003cli\u003eTransparency reforms: change award criteria\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal health priorities and disease programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGovernment emphasis on cancer (19.3M new cases in 2020, IARC), cardiovascular disease (17.9M deaths in 2019, WHO) and diabetes (537M adults in 2021, IDF) creates partnership and funding opportunities; national screening and prevention agendas (EU Beating Cancer Plan ~4bn EUR) expand addressable populations while alignment with public health goals eases access pathways and shifting budgets can reprioritize therapeutic focus.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDisease burden: cancer, CVD, diabetes—high prevalence\u003c\/li\u003e\n\u003cli\u003eScreening expansion increases eligible patient pools\u003c\/li\u003e\n\u003cli\u003ePublic health alignment improves reimbursement\/access\u003c\/li\u003e\n\u003cli\u003eBudget shifts may reallocate R\u0026amp;D and market focus\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEU HTA Jan 2025 and NICE £20–30k\/QALY compress margins; API risks grow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePrice controls, EU HTA (applied Jan 2025) and NICE thresholds (£20–30k\/QALY) intensify evidence and affect launches; Servier faces margin pressure from hospital tendering and centralized procurement (~14% EU GDP). R\u0026amp;D funding (Horizon Europe €95.5bn; France CIR €6–7bn) and Servier R\u0026amp;D €1.1bn (2023) support pipelines; API sourcing (~60% China\/India) and localization rules raise supply risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eIndicator\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEU HTA start\u003c\/td\u003e\n\u003ctd\u003eJan 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNICE threshold\u003c\/td\u003e\n\u003ctd\u003e£20–30k\/QALY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eServier 2023\u003c\/td\u003e\n\u003ctd\u003eRevenue €4.9bn; R\u0026amp;D €1.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHorizon Europe\u003c\/td\u003e\n\u003ctd\u003e€95.5bn (2021–27)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPI sourcing\u003c\/td\u003e\n\u003ctd\u003e~60% China\/India\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEU procurement\u003c\/td\u003e\n\u003ctd\u003e≈14% GDP\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how macro-environmental factors uniquely affect Servier across Political, Economic, Social, Technological, Environmental and Legal dimensions, with each category expanded into company-specific subpoints and examples. Backed by current data and forward-looking insights, it’s designed for executives, consultants and investors to identify risks, opportunities and support strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, visually segmented Servier PESTLE summary for meetings and presentations, easily editable with notes for regional or business-line context and shareable across teams to support risk discussions and strategic alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMacroeconomic cycles and payer budgets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMacroeconomic slowdowns compress public healthcare budgets and commonly delay payer reimbursements, forcing tighter 12–24 month funding cycles for drug adoption. OECD data show health spending averaged 8.8% of GDP in 2022 with roughly 73% publicly financed, so growth phases enable broader coverage and faster uptake. Servier must align launch sequencing to national fiscal calendars and deploy robust budget impact models, which become decisive in constrained environments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency volatility and cost base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFX swings affect euro-reported revenues and input costs; EUR\/USD and EM currency volatility compress reported sales. Hedging programs stabilize near-term cash flows but cannot offset structural currency depreciation. Servier's manufacturing footprint—about 21 production sites and presence in ~150 countries—shapes exposure via sourcing. Price corridors in regulated markets limit pass-through of cost increases.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeneric and biosimilar competition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePatent expiries trigger rapid price erosion, with generics often driving unit-price declines of 60–90% within 12 months and biosimilars producing discounts commonly in the 20–70% range. Tender-driven markets accelerate share loss — EU tenders frequently push prices to 20–40% of originator levels. Lifecycle management (reformulations, new indications) can preserve 30–50% of product value, so Servier’s pipeline must offset looming cliff effects.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D intensity and capital allocation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eServier's high R\u0026amp;D reinvestment sustains pipeline innovation but pressures operating margins, aligning with industry R\u0026amp;D intensity near 15%–18% of sales in 2023. Portfolio pruning and stage‑gate discipline concentrate capital on late‑stage oncology and immunology assets to improve ROI. ECB policy rates rising to about 4% in 2024 have increased cost of capital, shifting go\/no‑go thresholds and making partnering\/co‑development vital to share clinical risk.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eR\u0026amp;D intensity: industry ~15%–18% (2023)\u003c\/li\u003e\n\u003cli\u003eStage‑gate\/portfolio pruning: improves ROI by prioritizing late‑stage assets\u003c\/li\u003e\n\u003cli\u003ePartnering: risk and cost sharing in oncology\/immunology\u003c\/li\u003e\n\u003cli\u003eCost of capital: ECB ~4% (2024) raises investment hurdles\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmerging market growth and access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRising middle-class demand across Asia, LATAM and Africa is expanding volume opportunities for Servier; IQVIA reported emerging markets drove roughly 7–9% pharma sales growth in 2023–24. Tiered pricing and local manufacturing partnerships (in-country JV uptake up ~15% year-on-year in 2024) improve reach. However, currency volatility and inflation in key markets (inflation \u0026gt;10% in parts of LATAM\/SSA in 2024) can erode margins, and variable regulatory timelines delay launches.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket growth: emerging markets ~7–9% pharma sales growth (IQVIA 2023–24)\u003c\/li\u003e\n\u003cli\u003eLocal partnerships: +15% JVs uptake (2024)\u003c\/li\u003e\n\u003cli\u003eInflation risk: \u0026gt;10% in select LATAM\/SSA markets (2024)\u003c\/li\u003e\n\u003cli\u003eRegulatory variance: launch delays from months to years\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEU HTA Jan 2025 and NICE £20–30k\/QALY compress margins; API risks grow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMacroeconomic slowdowns tighten public budgets (health spending 8.8% GDP; 73% public, OECD 2022) and delay reimbursements, forcing 12–24m funding cycles. ECB rates ~4% (2024) raise cost of capital; R\u0026amp;D intensity ~15–18% (2023) pressures margins. FX and inflation in LATAM\/SSA (\u0026gt;10% in spots, 2024) plus emerging markets growth 7–9% (IQVIA 2023–24) shape launch\/pricing strategies.\n\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eIndicator\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eYear\/Source\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealth spend %GDP\u003c\/td\u003e\n\u003ctd\u003e8.8%\u003c\/td\u003e\n\u003ctd\u003e2022\/OECD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic finance\u003c\/td\u003e\n\u003ctd\u003e73%\u003c\/td\u003e\n\u003ctd\u003e2022\/OECD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eECB rate\u003c\/td\u003e\n\u003ctd\u003e~4%\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D intensity\u003c\/td\u003e\n\u003ctd\u003e15–18%\u003c\/td\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEM growth\u003c\/td\u003e\n\u003ctd\u003e7–9%\u003c\/td\u003e\n\u003ctd\u003e2023–24\/IQVIA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eServier PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Servier PESTLE Analysis you’ll receive after purchase—fully formatted and ready to use. This is the real, finished file with complete content and professional structure, no placeholders or teasers. After checkout you’ll be able to download this same document instantly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56162428911993,"sku":"servier-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/servier-pestle-analysis.png?v=1762700644","url":"https:\/\/portersfiveforce.com\/products\/servier-pestle-analysis","provider":"Porter's Five Forces","version":"1.0","type":"link"}